What records are connected here?
- Evidence lanes
- 3
- Source years
- 6
- Drugs@FDA applications
- 3
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
FDA-approved1,2Evidence: Smaller human trialsCancer
Lutetium Lu 177 dotatate is a radioactive drug made of a cyclic somatostatin-like peptide linked to the radioactive metal lutetium-177. It is the active ingredient in Lutathera.1,2 It is approved for adults and children 12 and older with somatostatin receptor-positive neuroendocrine tumors of the stomach, intestines and pancreas.1 In the randomized NETTER-1 trial of 229 patients described in the label, the disease progressed or the patient died in 23% of those given Lutathera and 69% of those given octreotide alone, but final overall survival did not differ significantly.1
| What it is | A radiolabeled somatostatin analogue: a cyclic peptide bound through a chelator to lutetium-177, which emits beta radiation, according to the Lutathera label.1 |
|---|---|
| FDA status | FDA-approved. Drugs@FDA lists Lutathera, NDA 208700, with an original approval date of January 26, 2018, and a second product, Bexlutry, NDA 218525, approved September 14, 2026. The cited label has no boxed warning.1,2,3 |
| Human evidence | One randomized, open-label, active-controlled trial (NETTER-1) in 229 patients with midgut carcinoid tumors, described in the label.1 |
| Evidence strength | Smaller controlled human trials. The cited sources include randomized or otherwise controlled human trials that are fully reported in a journal article or in posted registry results, but none meets the large-trial rule. How this label is assigned |
It is a radioactive peptide drug: an eight-amino-acid cyclic peptide related to somatostatin, linked by the chelator DOTA to lutetium-177, according to the label.1
In the United States it is the active ingredient of Lutathera, approved under NDA 208700, and of Bexlutry, approved under NDA 218525, according to Drugs@FDA.2,3
The label states that it binds most strongly to subtype 2 somatostatin receptors and is taken up into cells that carry them, including tumor cells, where beta radiation from lutetium-177 damages those cells and their neighbours.1
NETTER-1, a randomized, open-label trial described in the label, compared Lutathera plus long-acting octreotide with long-acting octreotide alone in 229 patients with progressive, well-differentiated midgut carcinoid tumors.1
Progression or death occurred in 27 of 116 patients (23%) given Lutathera and 78 of 113 (69%) given octreotide alone, and tumors shrank in 13% versus 4%. At the final analysis, overall survival did not differ significantly between the groups, according to the label.1
Evidence-strength label: Smaller controlled human trials. How this label is assigned
Yes. Drugs@FDA lists Lutathera, application NDA 208700, with an original approval date of January 26, 2018, and Bexlutry, application NDA 218525, approved September 14, 2026.2,3
The Lutathera label cited here (DailyMed SPL version 12, published January 16, 2026) states that it is indicated for adult and pediatric patients 12 years and older with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.1
The label has no boxed warning. Its warnings include radiation exposure, suppression of blood cell production, later myelodysplastic syndrome and leukemia, and kidney toxicity.1
HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Lutetium Lu 177 dotatate is not among them.4,5
Whether it lengthens survival: in NETTER-1, the final overall survival analysis showed no statistically significant difference from octreotide alone.1
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Go deeper
Everything PeptideScanner has collected for Lutetium Lu 177 dotatate: reviews, official-source readings, registry and literature records, and every change to this profile.
What the trial and literature lists cover. The trials and papers listed for Lutetium Lu 177 dotatate are a bounded selection, not every registration or paper about Lutetium Lu 177 dotatate. For the years before Lutetium Lu 177 dotatate was added, PeptideScanner took at most 25 ClinicalTrials.gov registrations that list Lutetium Lu 177 dotatate as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 25 PubMed papers that name Lutetium Lu 177 dotatate in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.
Evidence summary
FDA-approved as Lutathera for gastroenteropancreatic neuroendocrine tumors. In a randomized trial of 229 patients described in the label, Lutathera delayed progression compared with octreotide alone, but final overall survival did not differ significantly.↗↗
Status sources checked through November 15, 2026. See status sources and coverage →
Explore this profile’s cited source records →
An editorial human-evidence summary has not yet been published.
Living status brief
FDA-approved as Lutathera for gastroenteropancreatic neuroendocrine tumors. In a randomized trial of 229 patients described in the label, Lutathera delayed progression compared with octreotide alone, but final overall survival did not differ significantly.↗↗
The cited status sources were checked through November 15, 2026. This answer changes only through the profile’s visible version and correction history.
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
Clinical trials · source date November 16, 2026
ClinicalTrials.gov record NCT05278208↗Added to PeptideScanner November 16, 2026Clinical trials · added November 16, 2026
ClinicalTrials.gov record NCT05278208↗Source date November 16, 2026Clinical trials · added November 16, 2026
ClinicalTrials.gov record NCT04234568↗Source date November 13, 2026Clinical trials · added November 16, 2026
ClinicalTrials.gov record NCT04665739↗Source date November 12, 2026PeptideScanner currently has no selected safety records connected to this profile. That is a collection gap, not evidence that no such records exist.
PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.
Evidence Map v1
This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.
27 of 27 selected trial records include at least one phase value; 27 of 27 include a status value in the retained structured contract.
10 of 10 selected PubMed records include attributed title, venue, publication date, and publication-type fields.
Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.
Research hub
PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.
PeptideScanner retained ClinicalTrials.gov record NCT01578239 at 2026-11-16T01:36:36.861Z. Its registry update date was 2022-04-04, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.
PeptideScanner retained ClinicalTrials.gov record NCT03325816 at 2026-11-16T01:36:36.861Z. Its registry update date was 2021-03-16, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.
PeptideScanner retained ClinicalTrials.gov record NCT03457948 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-08-28, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.
10 with attributed title, venue, publication-date, and type metadata.
0 public history versions across these dated registry records; status labels apply only to each cited observation.
Original-submission application metadata connected by exact reviewed active-ingredient names.
FDA- and HHS-attributed document metadata connected by exact reviewed peptide-name matches, with official GovInfo PDFs.
Selected records span January 26, 2018 to November 16, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.
These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT05278208 at 2026-11-16T13:28:59.838Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT04234568 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-11-13, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT04665739 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT04750954 at 2026-11-16T02:15:32.969Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT05178693 at 2026-11-16T02:15:32.969Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT05691465 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT05773274 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT06955169 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-11-09, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.↗
Literature metadata
PubMed lists PMID 37184824 in European journal of drug metabolism and pharmacokinetics as Journal Article, with publication-date metadata of 2023-05-15 (day precision). PeptideScanner associated the retained record with the identity slug lutetium-lu-177-dotatate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 37883194 in Clinical nuclear medicine as Case Reports, Journal Article, with publication-date metadata of 2023-10-23 (day precision). PeptideScanner associated the retained record with the identity slug lutetium-lu-177-dotatate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT07910760 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-11-02, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.↗
Literature metadata
PubMed lists PMID 38451361 in Journal of neuro-oncology as Journal Article, with publication-date metadata of 2024-03-07 (day precision). PeptideScanner associated the retained record with the identity slug lutetium-lu-177-dotatate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Citations
Numbered markers in the text point here. Each link opens the original public record.
DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026
U.S. Food and Drug Administration · Official source · Source checked November 15, 2026
U.S. Food and Drug Administration · Official source · Source checked November 15, 2026
Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026